thalidomide has been researched along with Retinal Neovascularization in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Retinal Neovascularization: Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diabetic retinopathy is an ocular complication associated with the chronic endocrine disorder of diabetes mellitus." | 6.55 | Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. ( Behl, T; Goel, H; Kaur, I; Kotwani, A, 2017) |
| "Thalidomide is a well-known anti-angiogenic drug." | 5.35 | The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. ( Katz, G; Pri-Chen, S; Rabinowitz, R; Rosner, M; Spierer, A, 2008) |
| "Diabetic retinopathy is an ocular complication associated with the chronic endocrine disorder of diabetes mellitus." | 2.55 | Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. ( Behl, T; Goel, H; Kaur, I; Kotwani, A, 2017) |
| "Thalidomide has been shown to be anti-angiogenic via reduction of VEGF levels." | 1.36 | Intravitreal thalidomide reduces experimental preretinal neovascularisation without induction of retinal toxicity. ( Erber, R; Hammes, HP; Jonas, JB; Kamppeter, BA; Vom Hagen, F, 2010) |
| "Thalidomide is a well-known anti-angiogenic drug." | 1.35 | The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. ( Katz, G; Pri-Chen, S; Rabinowitz, R; Rosner, M; Spierer, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behl, T | 1 |
| Kaur, I | 1 |
| Goel, H | 1 |
| Kotwani, A | 1 |
| Dong, LF | 1 |
| Yao, J | 1 |
| Wang, XQ | 1 |
| Shan, K | 1 |
| Yang, H | 1 |
| Yan, B | 1 |
| Jiang, Q | 1 |
| Vom Hagen, F | 1 |
| Kamppeter, BA | 1 |
| Erber, R | 1 |
| Jonas, JB | 1 |
| Hammes, HP | 1 |
| Rabinowitz, R | 1 |
| Katz, G | 1 |
| Rosner, M | 1 |
| Pri-Chen, S | 1 |
| Spierer, A | 1 |
1 review available for thalidomide and Retinal Neovascularization
| Article | Year |
|---|---|
Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Diabetic Retinopathy; Humans; Neovascularizat | 2017 |
3 other studies available for thalidomide and Retinal Neovascularization
| Article | Year |
|---|---|
Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Movement; Cell Survival; Ch | 2015 |
Intravitreal thalidomide reduces experimental preretinal neovascularisation without induction of retinal toxicity.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Caspase 3; Down-Regulation; Intravitreal Injections; Mi | 2010 |
The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Dextrans; Disease Models, Animal; Fluoresceins; | 2008 |